📞 
— free, 24/7
— free, 24/7 — free, 24/7| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 0,2mg | 360 pills | £0.89 | £378.83 £322.00 Best Price | |
| 0,2mg | 180 pills | £0.94 | £198.62 £168.82 | |
| 0,2mg | 120 pills | £1.00 | £140.74 £119.63 | |
| 0,2mg | 90 pills | £1.05 | £111.80 £95.03 | |
| 0,2mg | 60 pills | £1.15 | £81.54 £69.31 | |
| 0,2mg | 30 pills | £1.36 | £48.66 £41.36 | |
| 0,4mg | 360 pills | £1.07 | £455.12 £386.85 Popular | |
| 0,4mg | 180 pills | £1.11 | £234.13 £199.01 | |
| 0,4mg | 120 pills | £1.22 | £172.31 £146.46 | |
| 0,4mg | 90 pills | £1.32 | £139.42 £118.51 | |
| 0,4mg | 60 pills | £1.49 | £105.22 £89.44 | |
| 0,4mg | 30 pills | £1.74 | £61.81 £52.54 |
Disclaimer: This information is for general guidance and does not replace professional medical advice. Seek personalised advice from a healthcare professional for individual health needs.
Benign prostatic hyperplasia (BPH) is common in older men and can create a partial blockage of the urinary tract. Symptoms may include a weak urine stream, hesitancy, and nocturnal urination. Contiflo belongs to a class of medicines called alpha-1 adrenergic receptor antagonists and is used to relieve these urinary symptoms by relaxing smooth muscle in the prostate and bladder neck.
The active ingredient in Contiflo is tamsulosin hydrochloride. This medicine is formulated to target receptors that are more prevalent in the prostate and urinary tract than in the blood vessels. The goal is to improve urine flow while limiting widespread blood pressure effects compared with non-selective alpha blockers.
Contiflo is prescribed to improve urinary symptoms associated with BPH and to help men regain more complete bladder emptying. It does not cure BPH, and ongoing evaluation is important to manage symptoms and monitor safety. The medication may be supplied as a single-ingredient product or as part of a broader treatment plan depending on local rules and clinical judgement.
When used appropriately, Contiflo can contribute to better daytime urinary function and reduced nocturia, which may improve quality of life. A clinician may assess symptoms with examination and, if needed, imaging or urine tests to rule out other conditions. The decision to start Contiflo rests on a healthcare professional’s assessment of benefits versus risks for the individual patient.
Contiflo is intended for the relief of urinary symptoms caused by BPH in men. The aim is to lessen obstruction in the urinary tract and improve flow, thereby reducing the effort required to urinate. The treatment is part of a broader approach to managing BPH that may include monitoring and lifestyle adjustments.
Common symptoms that may improve with Contiflo include a weaker or interrupted urine stream and the sense of incomplete bladder emptying. Other signals of BPH such as frequent urination, urgency, or increased night-time urination may also improve as flow improves. The medicine does not address all causes of bladder symptoms, so evaluation remains important if symptoms persist or worsen.
In addition to BPH-related symptoms, patients should be aware that other urinary or pelvic conditions can mimic these signs. If new or changing symptoms occur, or if there is fever, blood in the urine, or other concerning findings, a formal medical assessment should be sought. A healthcare professional will determine the most appropriate management plan.
A clinician may review symptoms over time to determine whether Contiflo remains the preferred option or whether alternative therapies should be considered. Ongoing assessment helps ensure that the benefits of symptom relief are balanced against potential side effects or interactions with other treatments.
Contiflo acts by blocking alpha-1A receptors, which are predominantly found in the smooth muscle of the prostate and bladder neck. By inhibiting these receptors, the smooth muscle relaxes, easing the passage of urine. This relaxation reduces resistance along the urinary tract and improves flow.
The effect of this mechanism is a gradual improvement in urinary symptoms rather than instant cure. The timing of symptom relief may vary between individuals, and some patients notice benefits within days to weeks of starting treatment. It is important to continue the medication as prescribed unless advised otherwise by a clinician.
Because the action is more pronounced in the urinary tract than in blood vessels, Contiflo may cause fewer systemic blood pressure effects than non-selective alpha blockers. Nevertheless, lightheadedness or dizziness can occur, particularly after the first dose or when rising from a sitting or lying position. This is monitored by healthcare professionals during follow-up visits.
The pharmacological approach of Contiflo reflects a targeted strategy to relieve obstruction-driven symptoms while limiting widespread cardiovascular effects. If other cardiovascular or metabolic conditions are present, a clinician may adjust treatment plans accordingly and monitor for interactions with concurrent medications.
Take Contiflo exactly as prescribed by a clinician. The exact dose and scheduling are tailored to the individual and may depend on severity of symptoms and tolerability. Do not change the dose or schedule without first consulting a healthcare professional.
Contiflo is usually prescribed as a once-daily regimen. The timing can be chosen to fit daily routines, and taking it after a meal may help with tolerability for some individuals. Consistency in timing is encouraged to maintain steady levels in the body.
Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet, as altering the medicine can affect how it works. If a dose is missed, contact a healthcare professional for guidance; do not take a double dose to make up for a missed one unless advised to do so by a clinician.
If dizziness or lightheadedness occurs, especially after the first dose or after a dose increase, sit or lie down and rise slowly. Driving or operating machinery should be avoided if these symptoms are present or if there is any concern about balance. A clinician can provide personalised safety advice based on health status and concurrent medications.
Do not take Contiflo if there is a known allergy to tamsulosin (the active ingredient) or to any component of the product. Severe allergic reactions require immediate medical attention. Individuals should inform a pharmacist or clinician about any known drug allergies before starting treatment.
Concomitant use of other alpha-1 blockers or agents that markedly lower blood pressure may increase the risk of dizziness or fainting. A healthcare professional will review current medicines to assess potential risks and determine the safest plan. If already taking such medicines, a change in therapy may be considered only under medical supervision.
Contiflo is not indicated for use in women or in children. In cases of pregnancy or breastfeeding, the guidance is to consult a clinician for appropriate management. Those with severe liver impairment or significant hepatic disease should be assessed by a clinician prior to initiation, as dose adjustments or alternative therapies may be necessary.
In uncertain situations or if any of the above conditions apply, consult a healthcare professional before starting Contiflo. The clinician can provide personalised advice based on medical history and current health status.
First-dose effects may include dizziness or fainting shortly after taking the initial dose. This risk is usually highest with the first dose and can be mitigated by taking it at night or by careful monitoring after initiation. Stand up slowly to reduce the chance of orthostatic symptoms.
A history of low blood pressure or fainting, especially in old age, requires careful monitoring. When Contiflo is used alongside other antihypertensive medicines, the possibility of additive blood pressure lowering effects exists. Blood pressure should be checked as directed by a clinician.
Ophthalmic considerations are relevant if cataract surgery is planned. Patients should inform the eye surgeon if Contiflo is being taken, because a condition called intraoperative floppy iris syndrome (IFIS) can occur during certain eye procedures. This information supports safe surgical planning.
Ask about all medicines, including over‑the‑counter drugs, vitamins, and herbal products. Some substances can alter how Contiflo works or increase side effects. A clinician will review interactions and provide guidance on safe combinations. In rare cases, severe skin reactions or other allergic responses may occur and require urgent medical care.
Common side effects include dizziness, headaches, fatigue, nasal congestion, and abnormal ejaculation. These effects are usually mild and may diminish with continued use. If problems persist or worsen, contact a healthcare professional for advice.
Less commonly, some individuals may experience low blood pressure or fainting, particularly after the first dose or when starting or increasing therapy. Allergic reactions such as rash, swelling, or breathing difficulties require urgent medical attention.
Serious but rare events include chest pain, swelling of the face or throat, severe skin reactions, or signs of an infection such as fever with unusual symptoms. If any of these occur, seek immediate medical help. The overall risk profile should be discussed with the clinician when starting treatment.
Most people tolerate Contiflo well, but persistent or bothersome side effects warrant a clinical review. The aim is to maintain symptom relief while minimising adverse effects through appropriate management strategies.
Some medicines can interact with Contiflo and affect blood pressure or cause dizziness. It is important to disclose all current medicines to a healthcare professional before starting Contiflo. A clinician can assess interactions and adjust therapy if needed.
Over-the-counter supplements or herbal products can also interact with Contiflo. A pharmacist or clinician should be consulted to review all products used regularly. If new medicines are prescribed or bought, recheck compatibility with Contiflo.
When changing or stopping any interacting medications, follow professional guidance. If unexpected symptoms occur after starting or changing a medicine, seek medical advice promptly to prevent complications. Ongoing communication with a healthcare professional supports safe and effective use.
Contiflo is intended for use in men with BPH and is not approved for use in pregnancy. The effects of tamsulosin during pregnancy have not been established in humans. Women who are pregnant or planning pregnancy should not participate in treatment with Contiflo unless specifically advised by a clinician.
The safety of Contiflo during breastfeeding has not been established. If a person is breast‑feeding, or plans to breast‑feed, a clinician can discuss the potential risks and alternatives. Special considerations apply when medication exposure is possible for infants.
In clinical practice, treatment decisions during pregnancy or breast feeding are guided by the balance of benefits and risks to the patient and, when applicable, to the infant. If there is any potential exposure during pregnancy, medical advice should be sought promptly.
For those seeking information on fertility considerations or family planning, a clinician can provide tailored guidance. The decision to continue Contiflo should be discussed in the context of overall health goals and treatment priorities.
Alcohol can lower blood pressure in some individuals, which may increase dizziness or fainting when Contiflo is taken. If consumption is planned, discuss safety with a clinician and monitor how tolerance is affected. Seek urgent medical help if fainting or severe dizziness occurs.
Improvements in urinary symptoms may appear gradually and can vary between individuals. Some patients notice relief within the first weeks of treatment, while others may require several weeks. If symptoms persist or worsen after a reasonable trial period, consult a clinician.
If a dose is missed, follow the clinician’s guidance. Do not double the next dose to compensate. In many cases, the missed dose can be skipped and the regular schedule resumed at the next planned time.
Contiflo may be used long-term under medical supervision when benefits continue to outweigh risks. Regular reviews are recommended to assess symptom control, blood pressure effects, and any side effects. If there is a change in health status, further assessment is advised.
Dizziness or lightheadedness can occur, especially after starting treatment or with dose changes. If these symptoms are present, driving or heavy machinery operation should be avoided until tolerance is established. Discuss concerns with a clinician if activities are affected.
Seek urgent medical advice if signs of a serious reaction appear, such as severe allergic symptoms, chest pain, fainting, or trouble breathing. In case of a life-threatening reaction, seek emergency care immediately. A clinician should be informed about any serious side effects to adjust treatment as needed.
There is a potential for blood pressure to be lowered by Contiflo, especially in combination with other blood pressure–lowering medicines. Symptoms may include dizziness or fainting. Blood pressure should be monitored as advised by a clinician.
Combination therapy may be appropriate in some cases, but it requires careful medical supervision. Some combinations can increase the risk of low blood pressure or other interactions. A clinician will determine whether combination therapy is suitable and safe.
Age alone is not a contraindication, but older adults may be more susceptible to dizziness or falls due to low blood pressure. A clinician will consider age-related factors, other medical conditions, and concurrent medications when prescribing Contiflo.
During eye surgery, a condition called intraoperative floppy iris syndrome (IFIS) can occur in individuals taking tamsulosin. It is essential to inform the eye surgeon about Contiflo use ahead of planned cataract or other eye procedures. This information helps ensure appropriate surgical planning.
Many patients continue treatment based on symptom relief and clinical judgment. The duration is tailored to the individual's response and health status and may involve ongoing assessment during routine follow-up visits. Any plan to discontinue should be discussed with a clinician.
Travel or changes in routine can affect medication schedules. Maintain consistent dosing times and ensure an adequate supply of Contiflo while away. If access to healthcare is limited, carry information about the medication and inform local clinicians if health concerns arise.
The official patient information leaflet supplied with Contiflo (the SmPC/PI) contains detailed instructions, contraindications, and safety information for healthcare professionals and patients. It is the primary reference for product-specific guidelines.
Consult a pharmacist or clinician if questions remain after reading the leaflet. Healthcare professionals can provide personalised advice about risks, benefits, and the management of any side effects in the context of individual health conditions.
Local regulatory bodies and professional organisations in the United Kingdom may publish guidance on the use of tamsulosin and related medicines. These sources can be consulted for general information about BPH management and pharmacovigilance.
In case of changes in health status, new medications, or concerns about interactions, seek advice promptly. Ongoing medical supervision supports safe and effective use of Contiflo and helps ensure appropriate treatment planning.
14–21 days. Free from £149.08 .
5–9 days. £22.36
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
